Post-ATU Study of Nivolumab

CompletedOBSERVATIONAL
Enrollment

350

Participants

Timeline

Start Date

March 9, 2017

Primary Completion Date

September 6, 2018

Study Completion Date

March 1, 2019

Conditions
Melanoma
Interventions
OTHER

Routine care

This study is an observational one - there is no change to the routine care. Patients received the Nivolumab independently of the study. Only data will be collected during this project.

Trial Locations (17)

13000

Hôpitaux de Marseille, Marseille

21000

Chu Dijon, Dijon

26000

Ch Valence, Valence

31000

Chu Toulouse, Toulouse

33000

Hopital St andré-CHU DE Bordeaux, Bordeaux

38700

CHU de Grenoble, Grenoble

59000

Chru Lille, Lille

63000

Chu Clermont-Ferrand, Clermont-Ferrand

64000

CH de PAU, Pau

69008

Centre Léon Bérard de Lyon, Lyon

69229

Hospices Civils de Lyon: Lyon Sud, Lyon

72000

CH du Mans, Le Mans

76038

CHU de Rouen, Rouen

80408

Chu Amiens, Amiens

94800

Institut Gustave Roussy, Villejuif

992100

AP-HP Hôpital Ambroise Paré, Paris

06000

CHU NICE, Nice

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Nantes University Hospital

OTHER

NCT03325257 - Post-ATU Study of Nivolumab | Biotech Hunter | Biotech Hunter